Activating Compound | Comment | Organism | Structure |
---|---|---|---|
additional information | contrary to meprin B only very little activation by trypsin treatment | Mus musculus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
1,10-phenanthroline | - |
Mus musculus | |
cysteine | - |
Mus musculus | |
EDTA | - |
Mus musculus | |
additional information | iodoacetate; L-trans-epoxysuccinyl-leucylamido-(4-guanidino)-butane (i.e. E-64); no inhibition by phosphoramidon; soybean trypsin inhibitor | Mus musculus |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
membrane | renal brush border membrane | Mus musculus | 16020 | - |
Metals/Ions | Comment | Organism | Structure |
---|---|---|---|
Zinc | metalloendopeptidase | Mus musculus |
Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|
additional information | - |
amino acid composition (of meprin A and B) | Mus musculus |
90000 | - |
4 * 90000, mouse, SDS-PAGE, reducing conditions | Mus musculus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
male ICR | - |
Mus musculus male ICR | - |
male ICR | - |
Posttranslational Modification | Comment | Organism |
---|---|---|
glycoprotein | complex-type glycosylation | Mus musculus |
Purification (Comment) | Organism |
---|---|
- |
Mus musculus |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
kidney | - |
Mus musculus | - |
Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
---|---|---|---|
additional information | - |
4.6673 mg azocasein/min/mg (untreated enzyme), 7.2512 mg azocasein/min/mg (trypsin-treated enzyme) | Mus musculus |
0.095 | - |
Tyr-Leu-Val-Cys(SO3-)-Gly-Glu-Arg-Gly | Mus musculus |
1.38 | - |
oxidized insulin B-chain, trypsin-treated enzyme | Mus musculus |
4.54 | - |
n-bradykinin | Mus musculus |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
azocasein + H2O | - |
Mus musculus | fragments of azocasein | - |
? | |
azocasein + H2O | - |
Mus musculus male ICR | fragments of azocasein | - |
? | |
bradykinin + H2O | - |
Mus musculus | Arg-Pro-Pro-Gly + Phe-Ser-Pro-Phe-Arg | - |
? | |
Insulin B-chain + H2O | prevalent cleavage sites are Gly20-Glu21, Phe24-Phe25 and Phe25-Tyr26 | Mus musculus | Hydrolyzed insulin B-chain | 15 different peptide fragments | ? | |
Insulin B-chain + H2O | 10 cleavage sites | Mus musculus | Hydrolyzed insulin B-chain | 15 different peptide fragments | ? | |
Insulin B-chain + H2O | oxidized form | Mus musculus | Hydrolyzed insulin B-chain | 15 different peptide fragments | ? | |
Insulin B-chain + H2O | prevalent cleavage sites are Gly20-Glu21, Phe24-Phe25 and Phe25-Tyr26 | Mus musculus male ICR | Hydrolyzed insulin B-chain | 15 different peptide fragments | ? | |
Insulin B-chain + H2O | 10 cleavage sites | Mus musculus male ICR | Hydrolyzed insulin B-chain | 15 different peptide fragments | ? | |
Insulin B-chain + H2O | oxidized form | Mus musculus male ICR | Hydrolyzed insulin B-chain | 15 different peptide fragments | ? | |
Tyr-Leu-Val-Cys(SO3-)-Gly-Glu-Arg-Gly + H2O | synthetic peptide derived from insulin B-chain | Mus musculus | ? | - |
? | |
Tyr-Leu-Val-Cys(SO3-)-Gly-Glu-Arg-Gly + H2O | synthetic peptide derived from insulin B-chain | Mus musculus male ICR | ? | - |
? |
Subunits | Comment | Organism |
---|---|---|
tetramer | 4 * 90000, mouse, SDS-PAGE, reducing conditions | Mus musculus |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
37 | - |
assay at | Mus musculus |
Temperature Stability Minimum [°C] | Temperature Stability Maximum [°C] | Comment | Organism |
---|---|---|---|
58 | - |
t1/2: 50 min | Mus musculus |